VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE
Vertex Pharmaceuticals announced the completion of its Phase III trial of Trikafta in children ages 6 through 11 years with cystic...


Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is safe for use in children with cystic fibrosis (CF) as young as age 6, data...


Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS
The European Commission and European Medicines Agency have approved the triple combination Kaftrio for use in certain cystic fibrosis...


Women With CF Use Combined Hormonal Contraceptives More Than Other Methods, Study Reports
Among women of childbearing age with cystic fibrosis (CF), the use of combined hormonal contraceptives containing both estrogen and...


CHMP Gives Positive Opinion to Vertex’s Triple Combination Therapy Kaftrio
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in...


Kalydeco Approved in Europe to Treat Children with R117H Mutation
The European Commission has approved Vertex’s Kalydeco (ivacaftor) for the treatment of children and adolescents with cystic fibrosis...


Real-world Use of Kalydeco for CF Highly Effective, Large-scale Analysis Shows
Kalydeco treatment led to fewer deaths, transplants, hospitalizations, and exacerbations in people with cystic fibrosis (CF) compared to...


This new treatment helps 90% of cystic fibrosis patients breathe better
Vertex’s Trikafta was the second-fastest FDA approval in history, and could help some 27,000 patients. In October 2019, Vertex...


UK NICE to Announce Decision on Vertex’s Therapy Trikafta in December
The National Institute for Health and Care Excellence (NICE) in the U.K. is currently in the process of evaluating Vertex...


Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO® (ivacaftor) will be available to eligible patients with...

